Exelixis (NASDAQ: EXEL) is set to give its latest quarterly earnings report on Tuesday, 2025-11-04. Here's what investors need to know before the announcement. Analysts estimate that Exelixis will ...

As previously reported, Guggenheim downgraded Exelixis (EXEL) to Neutral from Buy and removed the firm’s previous $45 price target on the shares.

Thinking about what to do with Exelixis stock right now? You are not alone. With the price at $36.13, Exelixis has caught the ...

Some on Wall Street weren’t too impressed with results from a pivotal trial that tested an Exelixis drug, zanzalintinib, in combination with Tecentriq.

Exelixis stock dips after Phase 3 data show modest survival gains from zanzalintinib and Tecentriq combo in colorectal cancer ...

Exelixis (EXEL) recently announced results from its global phase 3 STELLAR-303 trial, which evaluated zanzalintinib with ...

Guggenheim downgraded Exelixis (EXEL) to Neutral from Buy. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest ...

Exelixis, Inc. reported STELLAR-303 trial results for zanzalintinib plus atezolizumab vs. regorafenib in mCRC. Learn more ...

With data from the Phase III STELLAR-303 study in the books, Exelixis is plotting a 2025 regulatory application for ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2024, provided an update on progress toward achieving key corporate objectives ...

To access the webcast links, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. Replays will also be available at the same location for at least 30 ...

Exelixis, Inc. (Nasdaq: EXEL) today announced that the company’s Board of Directors has authorized the repurchase of up to an additional $500 million of the company’s common stock before December 31, ...